All News
ASBMR Recommendations on Secondary Fracture Prevention
The American Society for Bone and Mineral Research has developed multistakeholder consensus clinical recommendations for the prevention of secondary fractures for those aged 65 years and older after an initial hip or vertebral fracture.
Read ArticleIncreasingly Women are Choosing Subspecialty Careers
JAMA Internal Medicine has an analysis of the growing trend of more women enrolling in medical schools in the last few decades, such that more than half of US Med school matriculants in 2017 were women. Also in 2017, 42% of residents in internal medicine were women. The reported analy
Read ArticleIxekizumab vs. Adalimumab in Psoriatic Arthritis
The Annals of Rheumatic Disease reports a psoriatic arthritis study where in ixekizumab was non-inferior to adalimumab for achievement of ACR50 responses but was superior to adalimumab for achievement of PASI100 by week 24.
Read ArticleAnakinra Use in Hospitalized Gout Patients
While the efficacy and safety of interleukin 1 (IL-1) inhibitors (e.g., anakinra) in the acute management of gout and pseudogout has been repeatedly shown, the cost efficacy of such biologic therapy has rendered it impractical for most. A new retrospective study has shown that IL-1 inhibitors may be effective and appropriate for some medically complex, hospitalized patients with acute gout or calcium pyrophosphate crystal arthritis.
Read ArticleSimilar Outcomes for Hip Arthroplasty or Hemiarthroplasty in Hip Fracture
The NEJM reports on a randomized comparison of hemiarthroplasty and total hip arthroplasty in displaced femoral neck fractures and shows no difference in function and quality of life over 24 months.
Read ArticleUstekinumab Efficacy in Ulcerative Colitis
The NEJM reports the results of a one year trial wherein ustekinumab (UST) was shown to be effective at inducing and maintaining remission in patients with moderate-to-severe ulcerative colitis. Ustekinumab, currently approved for use in psoriasis, psoriatic arthritis and Crohn's disease, is a monoclonal antibody against the p40 subunit of interleukin-12 and interleukin-23.
Read ArticleFDA Approves Rituximab for Children with GPA
The U.S. Food and Drug Administration has approved Rituxan (rituximab) for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in children 2 years of age and older in combination with glucocorticoids.
This is the first approved treatment for children with vasculitis.

Dr. John Cush RheumNow ( View Tweet)

Dr. John Cush RheumNow ( View Tweet)

Links:
Dr. John Cush RheumNow ( View Tweet)



Gabe Charbonneau, MD gabrieldane ( View Tweet)

Dr. John Cush RheumNow ( View Tweet)

Dr. John Cush RheumNow ( View Tweet)

Links:
Dr. John Cush RheumNow ( View Tweet)

Links:
Dr. John Cush RheumNow ( View Tweet)

Dr. John Cush RheumNow ( View Tweet)

A&R reviews the inflammasome in autoimmune diseases. Pattern recognition recpt induce inflammasome activation, pro-caspase-1 converts to caspase-1 convertin pro-IL-1β and pro-IL-18 active IL-1β and IL-18; seen in RA, SLE, gout, Sjogrens https://t.co/JGadiEWQWf
Links:
Dr. John Cush RheumNow ( View Tweet)

Dr. John Cush RheumNow ( View Tweet)